

Customer: Jan Novák, Dlouhá 1, 30000 Plzeň, Czech Republic**Sample:**

Sample: 21-12345

Date received: 01.02.2021

Sample type: blood

Information provided by the customer

Name: Lassie DEMO**Breed:** Plemeno

Tattoo number: 1392013

Microchip: 123 456 789 012 345

Reg. number: REGQ12345

Date of birth: 1.1.2020

Sex: female

Date of sampling: 01.02.2021

The identity of the animal has been checked.

Result: Mutation was not detected (N/N)**Legend:** N/N = wild-type genotype. N/P = carrier of the mutation. P/P = mutated genotype (individual will be most probably affected with the disease). (N = negative, P = positive)**Explanation**

Presence or absence of c.1118C>T mutation in ATP13A2 gene causing Neuronal ceroid lipofuscinosis type 12 (NCL12) in Australian Cattle Dogs was tested. NCL is characterized by accumulation of lipid-like storage material (ceroid and lipofuscin) in nerve cells. The onset and clinical course of the disease are variable and individual. The affected dogs exhibit at least four of the following progressive neurological clinical symptoms: loss of vision, behavioural changes, cerebellar ataxia, tremors, decline of cognitive and motor functions, sleep disturbance and seizures. NCL includes neurological symptoms such as disorientation, states of anxiety and aggressive behaviour and problems with food intake. The degree of neurodegeneration increases with the age and mental abnormalities and spasm occur in all affected individuals. Changes in gait and posture can be observed – stumbling gait, limb stiffness. As there is no cure for this disease, it ultimately leads to death or euthanasia of the affected dog.

Mutation that causes NCL12 in Australian Cattle Dogs is inherited autosomally recessively which means that the disease develops only in those dogs who inherit mutated allele from both parents; disease affects dogs with P/P genotype only. The dogs with N/P genotype are considered carriers of the disease (heterozygotes). In offspring of two heterozygous animals following genotype distribution can be expected: 25 % N/N, 25 % P/P and 50 % N/P.

Method: SOPAgriseq_canine, ngs, accredited method

Date of issue: 06.02.2021

Date of testing: 01.02.2021 - 06.02.2021

Approved by: Mgr. Martina Šafrová, Laboratory Manager



Genomia is accredited in compliance with ISO/IEC 17025:2018 under #1549
Genomia s.r.o, Republikánská 6, 31200 Plzeň, Czech Republic
www.genomia.cz, laborator@genomia.cz, tel: +420 373 749 999

Report verification code is: 12AB-CD34-GENO-MIA0-EFGH. You can verify report online at www.genomia.cz

Without a written consent by the lab, the report must not be reproduced unless as a whole.

The result refers only to the tested sample, as received. Genomia is not responsible for the accuracy of the information provided by the customer.